Raija Kallio

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · JAMA · 2012 · 969 citations

Medicine, Oncology, Surgery +12

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · Journal of Clinical Oncology · 2015 · 231 citations

Medicine, Oncology, Immunotherapy +14

Effect of <i>KIT</i> and <i>PDGFRA</i> Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib

Heikki Joensuu, Eva Wardelmann, Harri Sihto et al. · JAMA Oncology · 2017 · 188 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · JAMA Oncology · 2020 · 180 citations · Full text

Medicine, Oncology, Surgery +15